Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children
BACKGROUND:Bacteremia caused by members of the Enterobacteriaceae can be life threatening. Appropriate antimicrobial therapy is critical to reducing morbidity and mortality. METHODS:This retrospective cohort study (2008–2011) was conducted in children and young adults (
Gespeichert in:
| Veröffentlicht in: | The Pediatric infectious disease journal 2015-11, Vol.34 (11), p.1203-1206 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1206 |
|---|---|
| container_issue | 11 |
| container_start_page | 1203 |
| container_title | The Pediatric infectious disease journal |
| container_volume | 34 |
| creator | Berkowitz, Nina M Spaeder, Michael C DeBiasi, Roberta L Campos, Joseph Singh, Nalini |
| description | BACKGROUND:Bacteremia caused by members of the Enterobacteriaceae can be life threatening. Appropriate antimicrobial therapy is critical to reducing morbidity and mortality.
METHODS:This retrospective cohort study (2008–2011) was conducted in children and young adults ( |
| doi_str_mv | 10.1097/INF.0000000000000885 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722185562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1722185562</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3565-72ecb4db625054adf6b9bf6423cb6d0303ce3eaa6fcba3a40e56d06322db74123</originalsourceid><addsrcrecordid>eNp9kEtPwzAMgCMEYmPwDxDqkUtHHk3aHmHaYBKPy-CEVCWpqwbapiStpv17OjYQ4oAvlu3PtvQhdE7wlOA0vlo-Lqb4dyQJP0BjwhkNcZrEh2iMk5SETIhkhE68fxsYFhF8jEZUMEyiNBmj13ndGmd08GAb25XgZLsJXsD53gczWyvTyM7YJljtR4V1wbzpwFkl9ZCM1CAhuPkqoDYyME0wK02VO2hO0VEhKw9n-zxBz4v5anYX3j_dLmfX96FmXPAwpqBVlCtBOeaRzAuhUlWIiDKtRI4ZZhoYSCkKrSSTEQY-tAWjNFdxRCiboMvd3dbZjx58l9XGa6gq2YDtfUZiSknCudii0Q7VznrvoMhaZ2rpNhnB2dZrNnjN_nod1i72H3pVQ_6z9C1yAJIdsLbVYMK_V_0aXFaCrLry_9ufOg6FTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1722185562</pqid></control><display><type>article</type><title>Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Berkowitz, Nina M ; Spaeder, Michael C ; DeBiasi, Roberta L ; Campos, Joseph ; Singh, Nalini</creator><creatorcontrib>Berkowitz, Nina M ; Spaeder, Michael C ; DeBiasi, Roberta L ; Campos, Joseph ; Singh, Nalini</creatorcontrib><description>BACKGROUND:Bacteremia caused by members of the Enterobacteriaceae can be life threatening. Appropriate antimicrobial therapy is critical to reducing morbidity and mortality.
METHODS:This retrospective cohort study (2008–2011) was conducted in children and young adults (<21 years of age) hospitalized with Enterobacteriaceae bacteremia with clinical signs and symptoms of infection. We investigated whether combination empiric antimicrobial therapy was superior to monotherapy for treatment. Monotherapy was defined as empiric therapy with a β-lactam agent alone. Combination therapy was defined as coadministration of a β-lactam agent with an aminoglycoside agent for at least 48 hours before the susceptibility data were known. Outcome was measured as the response to therapy (defined as the time to negative blood culture) and was compared among patients administered monotherapy versus combination therapy.
RESULTS:Of 203 episodes of Enterobacteriaceae bacteremia, 78 (38%) were caused by Klebsiella spp, 73 (36%) were caused by Escherichia coli, and 52 (26%) were caused by Enterobacter spp. Of 203 episodes of bacteremia caused by 3 organisms of greatest interest, 101 (50%) were treated with combination therapy. Patients with cancer were more likely to receive combination therapy (38% vs. 16%; P < 0.001); patients with gastrointestinal disease and those receiving total parenteral nutrition were more likely to receive monotherapy (58% vs. 39%; P = 0.006 and 54% vs. 37%; P = 0.013, respectively). There was no difference in outcome in patients receiving monotherapy versus combination therapy (P = 0.86).
CONCLUSION:Combination therapy consisting of a β-lactam agent and an aminoglycoside agent was not superior to monotherapy with a β-lactam agent alone for managing Enterobacteriaceae bacteremia in children and young adults.</description><identifier>ISSN: 0891-3668</identifier><identifier>EISSN: 1532-0987</identifier><identifier>DOI: 10.1097/INF.0000000000000885</identifier><identifier>PMID: 26301498</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adolescent ; Aminoglycosides - pharmacology ; Aminoglycosides - therapeutic use ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Bacteremia - drug therapy ; Bacteremia - epidemiology ; Bacteremia - microbiology ; beta-Lactams - pharmacology ; beta-Lactams - therapeutic use ; Child ; Child, Preschool ; Drug Therapy, Combination - methods ; Enterobacteriaceae - drug effects ; Enterobacteriaceae Infections - drug therapy ; Enterobacteriaceae Infections - epidemiology ; Enterobacteriaceae Infections - microbiology ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Retrospective Studies</subject><ispartof>The Pediatric infectious disease journal, 2015-11, Vol.34 (11), p.1203-1206</ispartof><rights>Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3565-72ecb4db625054adf6b9bf6423cb6d0303ce3eaa6fcba3a40e56d06322db74123</citedby><cites>FETCH-LOGICAL-c3565-72ecb4db625054adf6b9bf6423cb6d0303ce3eaa6fcba3a40e56d06322db74123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26301498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berkowitz, Nina M</creatorcontrib><creatorcontrib>Spaeder, Michael C</creatorcontrib><creatorcontrib>DeBiasi, Roberta L</creatorcontrib><creatorcontrib>Campos, Joseph</creatorcontrib><creatorcontrib>Singh, Nalini</creatorcontrib><title>Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children</title><title>The Pediatric infectious disease journal</title><addtitle>Pediatr Infect Dis J</addtitle><description>BACKGROUND:Bacteremia caused by members of the Enterobacteriaceae can be life threatening. Appropriate antimicrobial therapy is critical to reducing morbidity and mortality.
METHODS:This retrospective cohort study (2008–2011) was conducted in children and young adults (<21 years of age) hospitalized with Enterobacteriaceae bacteremia with clinical signs and symptoms of infection. We investigated whether combination empiric antimicrobial therapy was superior to monotherapy for treatment. Monotherapy was defined as empiric therapy with a β-lactam agent alone. Combination therapy was defined as coadministration of a β-lactam agent with an aminoglycoside agent for at least 48 hours before the susceptibility data were known. Outcome was measured as the response to therapy (defined as the time to negative blood culture) and was compared among patients administered monotherapy versus combination therapy.
RESULTS:Of 203 episodes of Enterobacteriaceae bacteremia, 78 (38%) were caused by Klebsiella spp, 73 (36%) were caused by Escherichia coli, and 52 (26%) were caused by Enterobacter spp. Of 203 episodes of bacteremia caused by 3 organisms of greatest interest, 101 (50%) were treated with combination therapy. Patients with cancer were more likely to receive combination therapy (38% vs. 16%; P < 0.001); patients with gastrointestinal disease and those receiving total parenteral nutrition were more likely to receive monotherapy (58% vs. 39%; P = 0.006 and 54% vs. 37%; P = 0.013, respectively). There was no difference in outcome in patients receiving monotherapy versus combination therapy (P = 0.86).
CONCLUSION:Combination therapy consisting of a β-lactam agent and an aminoglycoside agent was not superior to monotherapy with a β-lactam agent alone for managing Enterobacteriaceae bacteremia in children and young adults.</description><subject>Adolescent</subject><subject>Aminoglycosides - pharmacology</subject><subject>Aminoglycosides - therapeutic use</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - epidemiology</subject><subject>Bacteremia - microbiology</subject><subject>beta-Lactams - pharmacology</subject><subject>beta-Lactams - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug Therapy, Combination - methods</subject><subject>Enterobacteriaceae - drug effects</subject><subject>Enterobacteriaceae Infections - drug therapy</subject><subject>Enterobacteriaceae Infections - epidemiology</subject><subject>Enterobacteriaceae Infections - microbiology</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Retrospective Studies</subject><issn>0891-3668</issn><issn>1532-0987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtPwzAMgCMEYmPwDxDqkUtHHk3aHmHaYBKPy-CEVCWpqwbapiStpv17OjYQ4oAvlu3PtvQhdE7wlOA0vlo-Lqb4dyQJP0BjwhkNcZrEh2iMk5SETIhkhE68fxsYFhF8jEZUMEyiNBmj13ndGmd08GAb25XgZLsJXsD53gczWyvTyM7YJljtR4V1wbzpwFkl9ZCM1CAhuPkqoDYyME0wK02VO2hO0VEhKw9n-zxBz4v5anYX3j_dLmfX96FmXPAwpqBVlCtBOeaRzAuhUlWIiDKtRI4ZZhoYSCkKrSSTEQY-tAWjNFdxRCiboMvd3dbZjx58l9XGa6gq2YDtfUZiSknCudii0Q7VznrvoMhaZ2rpNhnB2dZrNnjN_nod1i72H3pVQ_6z9C1yAJIdsLbVYMK_V_0aXFaCrLry_9ufOg6FTw</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Berkowitz, Nina M</creator><creator>Spaeder, Michael C</creator><creator>DeBiasi, Roberta L</creator><creator>Campos, Joseph</creator><creator>Singh, Nalini</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201511</creationdate><title>Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children</title><author>Berkowitz, Nina M ; Spaeder, Michael C ; DeBiasi, Roberta L ; Campos, Joseph ; Singh, Nalini</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3565-72ecb4db625054adf6b9bf6423cb6d0303ce3eaa6fcba3a40e56d06322db74123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Aminoglycosides - pharmacology</topic><topic>Aminoglycosides - therapeutic use</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - epidemiology</topic><topic>Bacteremia - microbiology</topic><topic>beta-Lactams - pharmacology</topic><topic>beta-Lactams - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug Therapy, Combination - methods</topic><topic>Enterobacteriaceae - drug effects</topic><topic>Enterobacteriaceae Infections - drug therapy</topic><topic>Enterobacteriaceae Infections - epidemiology</topic><topic>Enterobacteriaceae Infections - microbiology</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berkowitz, Nina M</creatorcontrib><creatorcontrib>Spaeder, Michael C</creatorcontrib><creatorcontrib>DeBiasi, Roberta L</creatorcontrib><creatorcontrib>Campos, Joseph</creatorcontrib><creatorcontrib>Singh, Nalini</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Pediatric infectious disease journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berkowitz, Nina M</au><au>Spaeder, Michael C</au><au>DeBiasi, Roberta L</au><au>Campos, Joseph</au><au>Singh, Nalini</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children</atitle><jtitle>The Pediatric infectious disease journal</jtitle><addtitle>Pediatr Infect Dis J</addtitle><date>2015-11</date><risdate>2015</risdate><volume>34</volume><issue>11</issue><spage>1203</spage><epage>1206</epage><pages>1203-1206</pages><issn>0891-3668</issn><eissn>1532-0987</eissn><abstract>BACKGROUND:Bacteremia caused by members of the Enterobacteriaceae can be life threatening. Appropriate antimicrobial therapy is critical to reducing morbidity and mortality.
METHODS:This retrospective cohort study (2008–2011) was conducted in children and young adults (<21 years of age) hospitalized with Enterobacteriaceae bacteremia with clinical signs and symptoms of infection. We investigated whether combination empiric antimicrobial therapy was superior to monotherapy for treatment. Monotherapy was defined as empiric therapy with a β-lactam agent alone. Combination therapy was defined as coadministration of a β-lactam agent with an aminoglycoside agent for at least 48 hours before the susceptibility data were known. Outcome was measured as the response to therapy (defined as the time to negative blood culture) and was compared among patients administered monotherapy versus combination therapy.
RESULTS:Of 203 episodes of Enterobacteriaceae bacteremia, 78 (38%) were caused by Klebsiella spp, 73 (36%) were caused by Escherichia coli, and 52 (26%) were caused by Enterobacter spp. Of 203 episodes of bacteremia caused by 3 organisms of greatest interest, 101 (50%) were treated with combination therapy. Patients with cancer were more likely to receive combination therapy (38% vs. 16%; P < 0.001); patients with gastrointestinal disease and those receiving total parenteral nutrition were more likely to receive monotherapy (58% vs. 39%; P = 0.006 and 54% vs. 37%; P = 0.013, respectively). There was no difference in outcome in patients receiving monotherapy versus combination therapy (P = 0.86).
CONCLUSION:Combination therapy consisting of a β-lactam agent and an aminoglycoside agent was not superior to monotherapy with a β-lactam agent alone for managing Enterobacteriaceae bacteremia in children and young adults.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>26301498</pmid><doi>10.1097/INF.0000000000000885</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-3668 |
| ispartof | The Pediatric infectious disease journal, 2015-11, Vol.34 (11), p.1203-1206 |
| issn | 0891-3668 1532-0987 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1722185562 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Aminoglycosides - pharmacology Aminoglycosides - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacteremia - drug therapy Bacteremia - epidemiology Bacteremia - microbiology beta-Lactams - pharmacology beta-Lactams - therapeutic use Child Child, Preschool Drug Therapy, Combination - methods Enterobacteriaceae - drug effects Enterobacteriaceae Infections - drug therapy Enterobacteriaceae Infections - epidemiology Enterobacteriaceae Infections - microbiology Female Humans Infant Infant, Newborn Male Retrospective Studies |
| title | Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Empiric%20Monotherapy%20Versus%20Combination%20Therapy%20for%20Enterobacteriaceae%20Bacteremia%20in%20Children&rft.jtitle=The%20Pediatric%20infectious%20disease%20journal&rft.au=Berkowitz,%20Nina%20M&rft.date=2015-11&rft.volume=34&rft.issue=11&rft.spage=1203&rft.epage=1206&rft.pages=1203-1206&rft.issn=0891-3668&rft.eissn=1532-0987&rft_id=info:doi/10.1097/INF.0000000000000885&rft_dat=%3Cproquest_cross%3E1722185562%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1722185562&rft_id=info:pmid/26301498&rfr_iscdi=true |